Mock FDA, EMA & BIMO Inspection Readiness
Health authority inspections are a fact of life for pharma and biotech companies operating across global markets. Whether you are facing an FDA Bioresearch Monitoring (BIMO) inspection, an EMA or MHRA GMP inspection, or a Pre-Approval Inspection ahead of filing, the question regulators are really asking is the same: do your quality systems work in the real world, under pressure?
At Apotech we run realistic mock inspections that mirror exactly how the FDA, EMA, MHRA, and other global health authorities operate. We help you move away from “inspection panic” toward a culture of permanent readiness, whichever regulator is at your door.
Our team includes ex-FDA and ex-health authority consultants who have sat on the other side of the table. They handle the heavy lifting of compliance and give you clear, practical steps to close gaps before they become a finding.
Why Mock Inspections matter
Regulators want evidence that your Quality Management System (QMS) holds up in practice, not just on paper. A mock inspection tests your systems under the same pressure as the real thing, focusing on what inspectors scrutinize most: data integrity, management oversight, and your CAPA systems.
Instead of box-ticking, our ex-regulator consultants look at how your team handles challenge questions, escalates risks, and produces documents on demand. The goal is an operation that is not just compliant on paper but defensible in person, in front of a real investigator.
A single inspection finding can invalidate a pivotal study, delay an approval, or trigger a warning letter and broader investigation across your programs. Mock inspections find those weaknesses while you still have time to fix them.
Keep learning: Read our latest guide, FDA Mock Inspections: Types, Common Findings and How to Prepare, or explore GxP best practice explained.
Mock BIMO inspection services
Our mock BIMO inspections simulate the real inspection experience, led by ex-FDA consultants who understand both the FDA process and day-to-day clinical trial operations. We pressure-test the areas FDA investigators target most:
- Protocol and GCP compliance at the investigator site
- Informed consent documentation and process
- Source data verification and clinical data integrity
- Sponsor and CRO oversight, monitoring, and vendor management
- IRB and ethics committee records
- GLP and bioequivalence laboratory data
We prepare every stakeholder, identify regulatory vulnerabilities, and give you a prioritized remediation plan, so your study data stands up when it matters most.
Mock EMA, MHRA and global health authority inspections
FDA is only part of the picture. For companies supplying the EU, UK, and beyond, we run mock inspections replicating EMA, MHRA, and national competent authority expectations, from GMP and GDP inspections through to GVP pharmacovigilance and GCP clinical inspections.
Each regulator behaves differently in the room. Our ex-FDA and ex-health authority consultants prepare your team for the specific style, focus areas, and documentation expectations of the authority you are facing, so your readiness is calibrated to the real inspection, not a generic checklist. Our network covers 14+ authorities worldwide, including EMA, MHRA, Health Canada, TGA, Swissmedic, ANSM, and PMDA.
When to Schedule a Mock Inspection
Most organizations plan a mock inspection at these key moments:
- Before a submission or filing deadline — preparing for a Pre-Approval Inspection (PAI), a BIMO inspection tied to your NDA/BLA, or your first GMP audit
- After an inspection finding — confirming your corrective actions have genuinely fixed the problem and will survive a follow-up inspection or 483 response review
- During major change — keeping control while scaling up, merging, or restructuring your global operations
- For cause — when a specific risk, complaint, or data concern needs targeted assurance ahead of regulator attention
How our process works
1. The Readiness Review We start with an assessment of your current gaps. This often runs alongside our Quality Assurance support to give you a full picture of your inspection readiness.
2. The Simulation We run a realistic mock FDA, EMA, or BIMO inspection, including facility tours, site visits, and document reviews, tailored to your product, study, and risk level.
3. Interview Coaching How your team speaks to an investigator is decisive. Our ex-regulator consultants coach your SMEs to stay calm, clear, and technically precise during inspection interviews.
4. Practical Reporting No fluff. You receive a report structured like a real regulator's findings, including any simulated Form FDA 483 observations, with a clear remediation plan and 483 response support.
Inspection authorities we cover
We have experience conducting mock inspections that replicate the following authorities, including but not limited to:
FDA (USA), MHRA (UK), EMA (EU), Health Canada, TGA (Australia), HPRA (Ireland), Swissmedic (Switzerland), ANSM (France), PMDA (Japan), CDSCO (India), NMPA (China), ANVISA (Brazil), SAHPRA (South Africa), HSA (Singapore).
Trusted by top-tier teams worldwide
650+
Audits conducted in the last year
800
Network of expert GxP auditors
110
Countries covered
Why choose Apotech for mock inspections?
Our onsite or remote mock inspections help pharmaceutical, biotechnology, and medical device companies maintain the highest standards of readiness. Leveraging our deep in-house experience, we provide tailored simulations you can trust.
Ex-FDA and ex-health authority consultants
Our specialists include former FDA, EMA and other HA inspectors, alongside consultants who have led large-scale remediation programs. With a minimum of 20 years' experience, our ex-regulator team has run hundreds of successful simulations, including BIMO and PAI readiness, across the life sciences sector. You get the inspection prepared by the same kind of people who used to conduct them.
Global inspection specialists
Our network of 800+ senior consultants covers all GxP disciplines worldwide, with local-language fluency, so your team is ready for the specific behaviors of each regional regulator.
Competitive Pricing
By utilizing our local consultant network we minimize travel and expense costs, keeping mock inspections cost-effective without compromising on the seniority of the team reviewing your systems.
Flexible, client-centered service
From targeted for-cause simulations to global readiness programs, we adapt to your timeline and budget. A dedicated Project Manager keeps scheduling seamless and stakeholders aligned.
Featured case studies
GMP QA Consulting
GMP QA Consulting Introduction Global API Manufacturer The client was an API manufacturer, with a need for some support to cope with a deviation backlog. Apotech consultant: Two QA Consultants, with backgrounds in sterile devices. Types of Audits GMP Tools: Ishikawa, 5M Audit Locations Europe Scope of work Under the QA director supervision, our consultant…
Batch Release as EU Qualified Person
Batch Release as EU Qualified Person Introduction Our client is a vertically integrated company in chemical synthesis and manufacturing of generic Active Pharmaceutical Ingredients and Drug Products. Standards and references Scope of work Remote batch certification and release of medicinal products Provide regulatory expertise as requested Review Marketing Authorisation variations Perform training with impacted…
FAQs on mock inspections
At Apotech, we offer full transparency on our mock inspection services. We aim to make the process as simple to understand as possible and are always on hand to answer any questions you might have.
Here are some of the questions we get asked most often.
Helpful resources
2024 Pharmaceutical Inspections: Risk-Based, Remote-Ready, and Globally Harmonized
Staying audit-ready is no longer optional, it’s strategic! Based on EFPIA’s 2024 Inspection Survey, pharmaceutical manufacturers must align with increasingly global and risk-based inspection models. At Apotech, we help clients confidently meet these evolving expectations. Inspection compliance is consistent: no matter the type Whether a Pre-Approval Inspection (PAI), routine check, for-cause investigation, or surveillance audit,…
What is QMSR vs QSR? Understanding The FDA Final Rule and ISO 13485 Harmonization
The Quality Management System Regulation (QMSR) is the U.S. Food and Drug Administration’s (FDA) new rule replacing the Quality System Regulation (QSR) for medical devices. Finalized in February 2024, QMSR updates 21 CFR Part 820 by incorporating ISO 13485:2016 by reference, aligning U.S. quality system requirements with the internationally recognized medical device standard while retaining certain FDA-specific obligations. The…
How To Master The CAPA Process Step-by-Step: From Identification to Implementation
The Corrective and Preventive Action (CAPA) process is a core mechanism within Pharmaceutical and Biotech quality systems, designed to identify, address, and prevent issues that may impact compliance, product quality, and most importantly, patient safety. In regulated environments, CAPAs are not isolated actions but structured responses embedded within a wider quality management framework. CAPAs are commonly triggered by internal…